Ramacciotti, Eduardo 
; Agati, Leandro Barile ; Calderaro, Daniela ; Aguiar, Valéria Cristina Resende ; Spyropoulos, Alex C ; Oliveira, Caroline Candida Carvalho de; Santos, Jessica Lins dos; Volpiani, Giuliano Giova ; Sobreira, Marcone Lima ; Joviliano, Edwaldo Edner ; Bohatch Júnior, Milton Sérgio ; Fonseca, Benedito Antonio Lopes da ; Ribeiro, Maurício Serra; Dusilek, Cesar ; Itinose, Kenji ; Sanches, Suzanna Maria Viana ; Ramos, Karine de Almeida Araujo; Moraes, Nara Franzin de; Tierno, Paulo Fernando Guimarães Morando Marzocchi ; Oliveira, André Luiz Menezes de ; Tachibana, Adriano ; Chate, Rodrigo Caruso ; Santos, Marcus Vinícius Barbosa; Cavalcante, Bruno Bezerra de Menezes ; Moreira, Ricardo Cesar Rocha ; Chiann, Chang ; Tafur, Alfonso ; Fareed, Jawed ; Lopes, Renato D ; MICHELLE investigators
Fonte: The Lancet. Unidades: FMRP, IME
Assuntos: COVID-19, TROMBOCITOPENIA, BIOESTATÍSTICA
ABNT
RAMACCIOTTI, Eduardo et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, v. 399, n. 10319, p. 50-59, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(21)02392-8. Acesso em: 02 nov. 2025.APA
Ramacciotti, E., Agati, L. B., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., Oliveira, C. C. C. de, et al. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, 399( 10319), 50-59. doi:10.1016/S0140-6736(21)02392-8NLM
Ramacciotti E, Agati LB, Calderaro D, Aguiar VCR, Spyropoulos AC, Oliveira CCC de, Santos JL dos, Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, Fonseca BAL da, Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, Ramos K de AA, Moraes NF de, Tierno PFGMM, Oliveira ALM de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Fareed J, Lopes RD, MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial [Internet]. The Lancet. 2022 ; 399( 10319): 50-59.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S0140-6736(21)02392-8Vancouver
Ramacciotti E, Agati LB, Calderaro D, Aguiar VCR, Spyropoulos AC, Oliveira CCC de, Santos JL dos, Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, Fonseca BAL da, Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, Ramos K de AA, Moraes NF de, Tierno PFGMM, Oliveira ALM de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Fareed J, Lopes RD, MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial [Internet]. The Lancet. 2022 ; 399( 10319): 50-59.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S0140-6736(21)02392-8
